TESAMORELIN 10 MG

Tesamorelin is a synthetic 44-amino acid peptide that acts as a growth hormone-releasing hormone (GHRH) analogue, FDA-approved to treat excess abdominal visceral fat in HIV-infected adults with lipodystrophy. It increases IGF-1 levels, reducing fat by 15-17% over 26 weeks, but carries risks of glucose intolerance and injection site reactions.

National Institutes of Health (NIH) | (.gov) +1

What Tesamorelin Is Used For

• HIV-Associated Lipodystrophy: Approved in 2010 to reduce excess visceral abdominal fat (fat around organs) in patients with HIV receiving antiretroviral therapy.

• Off-Label/Research Potential: Investigated for reducing hepatic fat (fatty liver), reducing visceral adiposity in non-HIV individuals, and enhancing body composition (lean mass)

  .

How Tesamorelin Works
Tesamorelin acts as a synthetic GHRH analog that binds to receptors in the pituitary gland, stimulating the production and release of endogenous growth hormone. This rise in growth hormone increases serum insulin-like growth factor-1 (IGF-1) levels, which promotes lipolysis (fat breakdown) and reduces fat accumulation.

Common Side Effects and Warnings

• Injection Site Reactions: Common issues include pain, redness, swelling, and itching.

• Metabolic Effects: May increase risk of diabetes, worsen glucose tolerance, and elevate HbA1c levels.

• Other Symptoms: Joint/muscle pain, peripheral edema (swelling in limbs), and numbness.

• Contraindications: Not for use in pregnancy (Category X), children, patients with active cancer, or those with pituitary gland tumors.